Advertisement

Topics

Aerpio Therapeutics, Inc. Company Profile

14:51 EST 16th December 2018 | BioPortfolio

Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of Hypoxia-inducible Factor 1α (HIF‐1α). The Company’s lead program, AKB‐9778, is a first‐in‐class stabilizer of the Tie2 pathway and is in clinical development for diabetic macular edema. AKB‐4924, a HIF‐1α stabilizer, is in late preclinical development for inflammatory bowel disease. More information is available at www.aerpio.com.


News Articles [694 Associated News Articles listed on BioPortfolio]

Aerpio nets $42.3mm via FOPO

Ocular disease-focused Aerpio Pharmaceuticals Inc. netted $42.3mm through the follow-on offering of 11.7mm common shares at $3.85 each. The company concurrently announced it has uplisted to the Nasdaq...

Aerpio Announces Exclusive License Agreement with Gossamer Bio for AKB-4924

Aerpio Pharmaceuticals (OTCQB:ARPO), announced an exclusive global license agreement with a wholly owned subsidiary of Gossamer Bio, GB004, for the development and commercialization of Aerpio’s HIF-...

Aerpio Pharmaceuticals to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference

Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Of...

Aerpio Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC

Aerpio Pharmaceuticals, Inc. (Nasdaq:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Of...

Aerpio and Gossamer Bio Announce License Agreement

The agreement could bring sales milestones of Aerpio up to US$400 million, including US$20 million as an upfront payment, potential development, regulatory, sales milestones, and royalties on worldwid...

Aerpio grants Gossamer rights to IBD program

In a deal potentially worth up to $420mm, Aerpio Pharmaceuticals Inc. licensed Gossamer Bio Inc. exclusive global rights to develop and commercialize AKB4924 and related compounds for inflammatory bow...

Aerpio Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference

Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, to...

Deals this week: Adlai, Skyhawk, Aerpio Pharmaceuticals

Adlai Nortye Biopharma has raised $50m through a series B financing round from Yuanming Capital. Matrix Partners China, DT Capital,...Read More... The post Deals this week: Adlai, Skyhawk, Aerpio Phar...

PubMed Articles [462 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1286 Associated Companies listed on BioPortfolio]

Aerpio Therapeutics

Aerpio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel ...

Aerpio Therapeutics, Inc.

Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory b...

Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead program, AKB‐9778, is ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Aerpio Therapeutics, Inc." on BioPortfolio

We have published hundreds of Aerpio Therapeutics, Inc. news stories on BioPortfolio along with dozens of Aerpio Therapeutics, Inc. Clinical Trials and PubMed Articles about Aerpio Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aerpio Therapeutics, Inc. Companies in our database. You can also find out about relevant Aerpio Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...


Corporate Database Quicklinks



Searches Linking to this Company Record